Alemtuzumab: SC and IV administration in B-CLL

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1454, 2004-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alemtuzumab superior to chlorambucil for front-line CLL therapy

By  

Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Alemtuzumab: a costly alternative in CLL?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 605, 2010-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Alemtuzumab: an effective front-line option for CLL?

By  

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Alemtuzumab

By Frampton J.E.   Wagstaff A.J.  

Drugs, Vol. 63, Iss. 12, 2003-01 ,pp. : 1229-1243

Adis International

Access to resources Recommend Favorite

Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)

By  

Current Cancer Drug Targets, Vol. 9, Iss. 4, 2009-06 ,pp. : 510-518

Bentham Science Publishers

Access to resources Recommend Favorite